Everolimus

CAS: 159351-69-6

MF: C53H83NO14

MW: 958.22

EINECS: 621-003-9

Melting point NA

Boiling point 998.7±75.0 °C(Predicted)

density 1.18±0.1 g/cm3(Predicted)

Fp 2℃

storage temp. −20°C

Everolimus (IX) (SDZ-RAD), was developed by Novartis as an immunosuppressant to be used in conjunction with cyclosporin in transplantation allograft rejection and was recently approved in the US in 2003. Another natural product that had been approved for use in transplantation is rapamycin (sirolimus) as an inejectable agent. In an attempt to develop an orally bioavailable immunosuppressant agent, many companies attempted modification of rapamycin itself.